XOMA Corporation is a biotechnology company with a diverse portfolio of innovative therapeutic antibodies. The Company’s innovative product candidates are the result of its expertise in developing ground-breaking monoclonal antibodies, which have created new opportunities to potentially treat a wide range of endocrine diseases.
XOMA's scientific research produced a portfolio of five endocrine assets, each of which has the opportunity to address multiple indications. Two of the assets were developed through the XOMA Metabolic or XMet platform, which consists of separate classes of Selective Insulin Receptor Modulators (SIRMs) that could have a major impact on the treatment of metabolic disorders.
XOMA 358, XOMA's lead product candidate, is a is a fully human negative allosteric antibody that reduces insulin receptor activity. XOMA recently initiated a Phase 2 proof-of-concept (POC) study in patients with congenital hyperinsulinism (CHI) and initiated a Phase 2 POC study in another rare hyperinsulinemic hypoglycemic (low blood glucose caused by excessive insulin produced endogenously) indication, post-bariatric surgery (PBS) induced hyperinsulinism.
XOMA 129, a novel antibody fragment (Fab) from the XMetD program, designed as a potential treatment for severe acute hypoglycemia. Preclinical data was presented at the Endocrine Society Meeting (ENDO 2016) in April.
XOMA is located in Berkeley, California.
Jul 20, 2016
XOMA Receives Orphan Drug Designation in the European Union for XOMA 358 for Treatment of Congenital Hyperinsulinism
Jul 5, 2016
XOMA to Present at the Cantor Fitzgerald Healthcare Conference
View all »Events & Presentations
Jul 12, 2016 at 9:30 AM ET
Cantor Fitzgerald Healthcare Conference
Jun 9, 2016 at 2:00 PM ET
Jefferies 2016 Healthcare Conference